Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Acta Oncologica

Volumn 52, Issue 1, 2013, Pages 82-90

  Bjerre, Christina ^a,b   Knoop, Ann ^b   Bjerre, Karsten ^c   Larsen, Mathilde S ^d   Henriksen, Katrine L ^e   Lyng, Maria B ^f   Ditzel, Henrik J ^f   Rasmussen, Birgitte B ^d   Brünner, Nils ^a   Ejlertsen, Bent ^b,c   Lænkholm, Anne Vibeke ^g  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c Danish Breast Cancer Cooperative Group   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g SLAGELSE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; AROMATASE INHIBITOR; FORMALDEHYDE; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER HORMONE THERAPY; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; LYMPH NODE METASTASIS; MIDDLE AGED; PRIMARY TUMOR; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84871415828     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.734922     Document Type: Article

References (25)

1. Moore C S, C rocker S J. A n alternate perspective on the roles of TIMPs and MMPs in pathology . Am J Pathol 2012; 180 : 12 - 6 .
2. Coussens LM, F ingleton B, M atrisian LM. M atrix metalloproteinase inhibitors and cancer: Trials and tribulations . Science 2002; 295 : 2387 - 92 .
3. Koop S, K hokha R, S chmidt E E, M acDonald I C, M orris VL, Chambers AF, et al . Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth . Cancer Res 1994; 54 : 4791 - 7 . (Pubitemid 24276514)
4. Davies C, G odwin J, G ray R, C larke M, C utter D, D arby S, et al . Relevance of breast cancer hormone receptors and other factors to the effi cacy of adjuvant tamoxifen: Patientlevel meta-analysis of randomised trials . Lancet 2011; 378 : 771 - 84 .
5. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV . Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy . J Clin Oncol 2005; 23 : 7721 - 35 . (Pubitemid 46291836)
6. Liu XW, B ernardo MM, F ridman R, K im HR. T issue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway . J Biol Chem 2003; 278 : 40364 - 72 . (Pubitemid 37248605)
7. Mandlekar S, K ong AN. M echanisms of tamoxifen-induced apoptosis . Apoptosis 2001; 6 : 469 - 77 . (Pubitemid 33078758)
8. Neri A, M egha T, B ettarini F, T acchini D, M astrogiulio M G, Marrelli D, et al . Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases . Hum Pathol 2012; 43 : 1184-91 .
9. Nakopoulou L, G iannopoulou I, S tefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, et al . Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis . J Pathol 2002; 197 : 307 - 13 . (Pubitemid 34778300)
10. Schrohl A S, H olten-Andersen MN, P eters HA, L ook MP, Meijer-van Gelder ME, Klijn JG, et al . Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer . Clin Cancer Res 2004; 10 : 2289 - 98 . (Pubitemid 38445686)
11. Nakopoulou L, G iannopoulou I, L azaris AC, A lexandrou P, Tsirmpa I, Markaki S, et al . The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells . APMIS 2003; 111 : 1027 - 36 . (Pubitemid 37521896)
12. McShane LM, A ltman D G, S auerbrei W, T aube S E, G ion M, Clark GM . REporting recommendations for tumour MARKer prognostic studies (REMARK) . Eur J Cancer 2005; 41 : 1690 - 6 . (Pubitemid 41132629)
13. Larsen M S, B jerre K, G iobbie-Hurder A, L aenkholm AV, Henriksen KL, Ejlertsen B, et al . Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy . Acta Oncol 2012; 51 : 781-9 .
14. Moller S, J ensen MB, E jlertsen B, B jerre KD, L arsen M, Hansen HB, et al . The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30 - years experience and future promise . Acta Oncol 2008; 47 : 506 - 24 . (Pubitemid 351878431)
15. Henriksen K L, R asmussen B B, L ykkesfeldt AE, M oller S, Ejlertsen B, Mouridsen HT . Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: A comparison between whole sections and tissue microarrays . J Clin Pathol 2007; 60 : 397 - 404 . (Pubitemid 46596559)
16. Willemoe G L, H ertel P B, B artels A, J ensen M B, B alslev E, Rasmussen BB, et al . Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n - 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study . Eur J Cancer 2009; 45 : 2528 - 36 .
17. Goldhirsch A, W ood WC, C oates A S, G elber RD, Thurlimann B, Senn HJ . Strategies for subtypes - dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 . Ann Oncol 2011; 22 : 1736 - 47 .
18. Lipton A, L eitzel K, C haudri-Ross HA, E vans DB, A li SM, Demers L, et al . Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer . J Clin Oncol 2008; 26 : 2653 - 8 .
19. Lipton A, A li SM, L eitzel K, D emers L, E vans DB, Hamer P, et al . Elevated plasma tissue inhibitor of metalloproteinase- 1 level predicts decreased response and survival in metastatic breast cancer . Cancer 2007; 109 : 1933 - 9 . (Pubitemid 46744185)
20. Wu ZS, W u Q, Y ang JH, W ang HQ, D ing XD, Y ang F, et al . Prognostic signifi cance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer . Int J Cancer 2008; 122 : 2050 - 6 .
21. Bigelow R L, Williams B J, Carroll J L, Daves L K, Cardelli J A . TIMP-1 overexpression promotes tumorigenesis of MDAMB- 231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro . Breast Cancer Res Treat 2009; 117 : 31 - 44 .
22. Kuvaja P, H ulkkonen S, P asanen I, S oini Y, L ehtonen S, Talvensaari-Mattila A, et al . Tumor tissue inhibitor of metalloproteinases- 1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratifi cation of prognosis together with nodal status . Exp Cell Res 2012; 318 : 1094 - 103 .
23. Cheang MC, C hia SK, V oduc D, G ao D, L eung S, S nider J, et al . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer . J Natl Cancer Inst 2009; 101 : 736 - 50 .
24. Nielsen T O, P arker JS, L eung S, V oduc D, E bbert M, Vickery T, et al . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer . Clin Cancer Res 2010; 16 : 5222 - 32 .
25. Iwamoto T, B ooser D, V alero V, M urray J L, K oenig K, Esteva FJ, et al . Estrogen receptor (ER) mRNA and ERrelated gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry . J Clin Oncol 2012; 30 : 729 - 34 .